This is a summary of the European public assessment report (EPAR) for Docetaxel Kabi. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing ... European Medicines Agency, 1 day ago
Regulatory experts stressed that the Indian pharma cos should put special focus on following all the data integrity requirements to avoid crackdown by regulatory agencies. This warning comes in the wake of growing incidence of issuance of letters by ...PharmaBiz, 1 week ago
Crizotinib is branded as Xalkori, while Axitinib as Inlyta by Pfizer . Fresenius Kabi has informed its decision to withdraw four petitions against patent of Crizotinib and one against Axitinib with the Intellectual Property Appellate Board (IPAB) ...4 Traders, 3 weeks ago Pfizer : FRESENIUS KABI WITHDRAWS PATENT PLEAS AGAINST PFIZER 4 Traders, 3 weeks ago Fresenius Kabi withdraws patent pleas against Pfizer Financial Express, 3 weeks ago
Cancer drug major Fresenius Kabi Oncology Ltd, the Indian arm of Germany-based Fresenius Kabi, has withdrew revocation petitions against cancer drug patents owned by Pfizer and its subsidiaries as the former has "lost business interest" in the molecules. The ...Business Standard, 3 weeks ago
@FiercePharma: Tops on FPMarketing Weds: Can Sanofi/Regeneron's new data one-up Amgen in megablockbuster PCSK9 field? Article | Follow @FiercePharma @EricPFierce: Agents in EU seize €10M worth of counterfeit drugs, as well as cash and luxury ...FiercePharma, 3 weeks ago
on your WebpageAdd Widget >Get your members hooked!